Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Generex Biotechnology Corporation (OTCPK:GNBT) is 157.860400. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Generex Biotechnology Corporation (OTCPK:GNBT) is 109.558700. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 117.213000.
The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Generex Biotechnology Corporation (OTCPK:GNBT) is 82. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Generex Biotechnology Corporation (OTCPK:GNBT) is 89.
Taking a step further we can take a look at various other valuation metrics. Generex Biotechnology Corporation (OTCPK:GNBT) has a Price to Book ratio of -15.795152. This ratio is calculated by dividing the current share price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some other ratios, the company has a Price to Cash Flow ratio of -22.255895, and a current Price to Earnings ratio of 18.687976. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued.
The Free Cash Flor Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The average FCF of a company is determined by looking at the cash generated by operations of the company. The Free Cash Flow Yield 5 Year Average of Generex Biotechnology Corporation (OTCPK:GNBT) is -0.010665.
The Return on Invested Capital (aka ROIC) for Generex Biotechnology Corporation (OTCPK:GNBT) is -8.694679. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. It tells investors how well a company is turning their capital into profits. The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital. The employed capital is calculated by subrating current liabilities from total assets. Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years. The ROIC Quality of Generex Biotechnology Corporation (OTCPK:GNBT) is 1.309343. This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC. The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets). The ROIC 5 year average of Generex Biotechnology Corporation (OTCPK:GNBT) is -3.530403.
Generex Biotechnology Corporation (OTCPK:GNBT) presently has a current ratio of 0.13. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. The ratio is simply calculated by dividing current liabilities by current assets. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Typically, the higher the current ratio the better, as the company may be more capable of paying back its obligations.
Quant Ranks (ERP5, Gross Margin, F Score)
The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Generex Biotechnology Corporation (OTCPK:GNBT) is 17537. The lower the ERP5 rank, the more undervalued a company is thought to be.
The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of Generex Biotechnology Corporation (OTCPK:GNBT) is 5. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.
Investors may be interested in viewing the Gross Margin score on shares of Generex Biotechnology Corporation (OTCPK:GNBT). The name currently has a score of 1.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.
The Price Index is a ratio that indicates the return of a share price over a past period. The price index of Generex Biotechnology Corporation (OTCPK:GNBT) for last month was 2.01511. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month. If the ratio is less than 1, then we can determine that there has been a decrease in price. Similarly, investors look up the share price over 12 month periods. The Price Index 12m for Generex Biotechnology Corporation (OTCPK:GNBT) is 25.74624.
Price Range 52 Weeks
Some of the best financial predictions are formed by using a variety of financial tools. The Price Range 52 Weeks is one of the tools that investors use to determine the lowest and highest price at which a stock has traded in the previous 52 weeks. The Price Range of Generex Biotechnology Corporation (OTCPK:GNBT) over the past 52 weeks is 1.000000. The 52-week range can be found in the stock’s quote summary.